Therapie der Mitralklappeninsuffizienz beim Hund – Was, wann und wieviel?

Die Mitralklappeninsuffizienz kommt in der tierärztlichen Praxis sehr häufig vor. Dennoch muss bei jedem Patienten individuell entschieden werden, wann eine medikamentelle Therapie sinnvoll ist. Lesen Sie dazu über die Schweregradeinteilung der Mitralklappeninsuffizienz und welche neuen Therapieempfehlungen es gibt.

• Literatur

• 1 Atkins C, Bonagura J, Ettinger S. et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med 2009; 23 (06) 1142-1150
• 2 Boswood A, Gordon SG, Haggstrom J. et al. Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study. J Vet Intern Med 2018; 32 (01) 72-85
• 3 Haggstrom J, Boswood A, OʼGrady M. et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. J Vet Intern Med 2008; 22 (05) 1124-1135
• 4 Chetboul V, Pouchelon JL, Menard J. et al. Short-Term Efficacy and Safety of Torasemide and Furosemide in 366 Dogs with Degenerative Mitral Valve Disease: The TEST Study. J Vet Intern Med 2017; 31 (06) 1629-1642
• 5 Bernay F, Bland JM, Haggstrom J. et al. Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. J Vet Intern Med 2010; 24 (02) 331-341
• 6 Wess G. The Valve Study: Is Triple Therapy Superior to Double Therapy for Failure Treatment due to Endocardiosis? ACVIM Forum 2017: National Harbor, 8. – 10. Juni.